Protagonist Therapeutics Files 8-K on Financials
Ticker: PTGX · Form: 8-K · Filed: May 6, 2025 · CIK: 1377121
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Protagonist Therapeutics filed an 8-K on May 6, 2025, detailing financial results and statements.
AI Summary
Protagonist Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond the reporting of these items.
Why It Matters
This 8-K filing indicates that Protagonist Therapeutics is providing updates on its financial condition and results of operations, which is crucial for investors to assess the company's performance.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not inherently present new risks.
Key Players & Entities
- Protagonist Therapeutics, Inc. (company) — Registrant
- May 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-37852 (identifier) — Commission File Number
- 98-0505495 (identifier) — IRS Employer Identification No.
- 7707 Gateway Blvd. , Suite 140 Newark , Calif (address) — Business Address
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but specific figures are not detailed in the provided text.
When was the earliest event reported in this filing?
The earliest event reported was on May 6, 2025.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is Protagonist Therapeutics, Inc.'s Commission File Number?
The Commission File Number is 001-37852.
Where is Protagonist Therapeutics, Inc. located?
The company's business address is 7707 Gateway Blvd., Suite 140, Newark, California.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 6, 2025 regarding Protagonist Therapeutics, Inc (PTGX).